Waldenstrom’s Webinar for patients and carers

Have you been recently diagnosed with Waldenstrom Macroglobulinemia (WM)?  Or would you like to understand more about WM, the treatment options and clinical trials?

Professor Trotman is a Sydney based clinical haematologist who has steered the Concord Research Unit towards leading recruitment in clinical trials in many lymphoma subtypes, including Waldenstrom’s Macrogobulinemia. Dr Trotman is the current chair of the Australasian Leukaemia and Lymphoma Group (ALLG) and has mentored clinical research fellow Dr Ibrahim Tohidi-Esfahani who was the co principal investigator on the WM Study Involving CART-WHEEL (WhiMSICAL). Dr Ibrahim Tohidi-Esfahani, together with Professor Judith Trotman, spearheaded an international team of patient and clinician investigators to expand the reach of WhiMSICAL, the world-first global patient-derived data registry for Waldenstrom’s Macroglobulinemia.

Join Professor Judith Trotman and Dr Ibrahim Tohidi-Esfahani as they provide you with information on WM

 

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Wednesday 24th of May 2023
Time: 4:00pm AEST - 5:30pm AEST

Support and information

Contact Lymphoma Australia Today!

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.